Data on posaconazole serum levels of patients on prophylaxis with delayed-release tablets or oral suspension during intensive chemotherapy for acute myeloid leukemia and myelodysplastic syndrome are scarce. In this analysis, the proportion of patients with acute myeloid leukemia/myelodysplastic syndrome achieving posaconazole target concentrations with delayed-release tablets was higher than with oral suspension.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11127630 | PMC |
| http://dx.doi.org/10.1093/ofid/ofae263 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors affecting posaconazole plasma concentrations: a meta-analysis and systematic review.
Front Pharmacol
December 2024
Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Background: Posaconazole is a potent antifungal agent widely used to manage invasive fungal infections, especially in immunocompromised individuals. Achieving optimal therapeutic concentrations of posaconazole can be challenging due to interpatient variability, the availability of multiple formulations, and various dosing strategies.
Methods: We conducted a systematic search of PubMed, EMBASE, and the Cochrane Library to identify studies evaluating factors that influence blood concentrations of posaconazole.
Clinical Implications of Proton Pump Inhibitors and Vonoprazan Micro/Nano Drug Delivery Systems for Gastric Acid-Related Disorders and Imaging.
Nanotheranostics
November 2024
Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi-221005, India.
Article Synopsis
- Gastric acid-related disorders like peptic ulcers and gastroesophageal reflux disease (GERD) are primarily caused by excessive stomach acid or bacterial infections, and can be treated with medications such as proton pump inhibitors (PPIs) and vonoprazan.
- While PPIs work by irreversibly blocking the proton pump in stomach cells, vonoprazan inhibits acid secretion by targeting the potassium-competitive acid blocker receptor, making it one of the most effective options for GERD.
- The review highlights various innovative micro/nano formulations of these medications, as well as the crucial role of imaging techniques like CT scans and endoscopy in diagnosing and managing these gastric acid disorders.
Therapeutic drug monitoring of posaconazole delayed-release tablets and injections in pediatric patients.
Antimicrob Agents Chemother
December 2024
Department of Pharmacy, Shanghai Children's Medical Center, School of Medicine, Shanghai JiaoTong University, Shanghai, China.
This study aimed to investigate the dose and trough concentration () of posaconazole delayed-release tablets and injections, and their correlation with efficacy and safety in pediatric patients. Patients younger than 18 years old received posaconazole delayed-release tablets or injections for prophylaxis or treatment of invasive fungal disease (IFD). Blood samples were collected to determine the plasma s, and dose regimen adjustments were made if necessary.
View Article and Find Full Text PDFDeferiprone in Alzheimer Disease: A Randomized Clinical Trial.
JAMA Neurol
November 2024
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Australia.
Importance: Interventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide. Elevated brain iron observed in AD has been associated with accelerated cognitive decline and may be a tractable drug target.
Objective: To investigate whether the brain-permeable iron chelator deferiprone slows cognitive decline in people with AD.
Evaluation of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Recipients.
Transpl Infect Dis
November 2024
Department of Clinical Pharmacy, University of California, San Francisco, California, USA.
Article Synopsis
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!